A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
Condition: IgG4 Related Disease · Sponsor: Amgen
About this study
This study aims to evaluate the efficacy and safety of inebilizumab for the prevention of flare of Immunoglobulin G4-related disease (IgG4-RD).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (72)
| Viela Bio Investigative Site | Palo Alto, California, United States | — |
| Viela Bio Investigative Site | Atlanta, Georgia, United States | — |
| Viela Bio Investigative Site | Baltimore, Maryland, United States | — |
| Viela Bio Investigative Site | Boston, Massachusetts, United States | — |
| Viela Bio Investigative Site | Buenos Aires, Argentina | — |
| Viela Bio Investigative Site | Mendoza, Argentina | — |
| Viela Bio Investigative Site | Auchenflower, Queensland, Australia | — |
| Viela Bio Investigative Site | Adelaide, South Australia, Australia | — |
| Viela Bio Investigative Site | Fitzroy, Australia | — |
| Viela Bio Investigative Site | Sherbrooke, Canada | — |
| Viela Bio Investigative Site 1 | Toronto, Canada | — |
| Viela Bio Investigative Site 2 | Toronto, Canada | — |
+ 60 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04540497